Back

Ceftazidime-Avibactam Resistance in Escherichia coli Primarily Mediated by blaNDM-5 with Emergent Ceftazidime-Avibactam/Aztreonam Resistance Linked to blaCMY-42 Variants

Shropshire, W. C.; Borjan, J.; Khan, A.; Young, A.; Chung, J. K.; Wu, C.-T.; Manzanares, A.; Bhatti, M. M.; Vuong, N. N.; Handley, G.; Spallone, A.; Chemaly, R. F.; Shelburne, S.

2025-12-07 infectious diseases
10.64898/2025.12.05.25341718 medRxiv
Show abstract

Ceftazidime-avibactam (CZA) has revolutionized care for carbapenem-resistant Enterobacterales infections, yet increasing New Delhi metallo-{beta}-lactamase (NDM) prevalence has driven use of CZA plus aztreonam (CZA/ATM). We performed a comprehensive analysis of CZA-resistant Escherichia coli (CZA-R-Ec) at a tertiary cancer center (2017-2024) by integrating clinical data, comparative genomics, and CZA/ATM susceptibility testing. CZA-R-Ec were isolated from forty-eight unique patients of whom 28 (58%) had confirmed infection. Oxford Nanopore Technologies long-read sequencing performed on 34 isolates from unique patients showed a diverse population enriched for ST167 (35%). Most sequenced isolates carried blaNDM-5 (26/34, 76%); among blaNDM-5 strains, 88% (23/26) harbored PBP3 YRI(K/N) insertions. Eleven isolates (32%) carried blaCMY variants, predominantly blaCMY-42. BlaNDM-5 and blaCMY genes were largely plasmid-borne (IncF-type and IncI-{gamma}/K1) in distinct genomic contexts. Among 32 confirmed CZA-R and ATM-R index isolates, 21 (66%) were CZA/ATM synergy positive to CZA/ATM (MIC[≤]4 {micro}g/mL; SYN+). Compared to patients with SYN+ strains, patients with SYN-isolates (CZA/ATM MIC>4 {micro}g/mL) were significantly more likely to have had a prior E. coli infection (73% vs. 0%, P-value=1.6x10-5). SYN- isolates were strongly associated with blaCMY carriage (81% vs 9% in SYN+; adjusted P-value=4x10-4). Among 18 confirmed CZA-R-Ec bacteremias, 15 carried blaNDM; 14/15 (92%) received CZA/ATM and all responded clinically. In conclusion, CZA-R-Ec at our center are dominated by PBP3-insertion, blaNDM-5-positive lineages, for which CZA/ATM retains substantial in vitro activity and clinical efficacy. However, recent carbapenem exposure and prior E. coli infection identifies patients at risk for CZA/ATM non-synergy, frequently linked to blaCMY-42 variant positive isolates.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
The Lancet Microbe
43 papers in training set
Top 0.1%
14.5%
2
Journal of Antimicrobial Chemotherapy
43 papers in training set
Top 0.1%
6.7%
3
Genome Medicine
154 papers in training set
Top 0.8%
6.7%
4
Nature Communications
4913 papers in training set
Top 33%
4.8%
5
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 0.5%
4.8%
6
Journal of Clinical Microbiology
120 papers in training set
Top 0.4%
4.8%
7
The Journal of Infectious Diseases
182 papers in training set
Top 0.9%
3.9%
8
Clinical Infectious Diseases
231 papers in training set
Top 2%
3.5%
9
JCI Insight
241 papers in training set
Top 2%
3.0%
50% of probability mass above
10
mBio
750 papers in training set
Top 5%
2.8%
11
JAC-Antimicrobial Resistance
13 papers in training set
Top 0.1%
2.7%
12
Emerging Infectious Diseases
103 papers in training set
Top 0.9%
2.6%
13
The Lancet Infectious Diseases
71 papers in training set
Top 1%
2.1%
14
Microbial Genomics
204 papers in training set
Top 0.9%
2.1%
15
PLOS Medicine
98 papers in training set
Top 2%
1.8%
16
mSphere
281 papers in training set
Top 3%
1.7%
17
Open Forum Infectious Diseases
134 papers in training set
Top 1%
1.7%
18
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.7%
19
International Journal of Antimicrobial Agents
15 papers in training set
Top 0.3%
1.7%
20
Cell Reports Medicine
140 papers in training set
Top 4%
1.5%
21
Journal of Infection
71 papers in training set
Top 2%
1.5%
22
eLife
5422 papers in training set
Top 47%
1.3%
23
Nature Medicine
117 papers in training set
Top 3%
1.3%
24
Clinical Microbiology and Infection
60 papers in training set
Top 0.8%
1.2%
25
Nature Microbiology
133 papers in training set
Top 3%
1.2%
26
New England Journal of Medicine
50 papers in training set
Top 0.7%
0.9%
27
Gastroenterology
40 papers in training set
Top 2%
0.8%
28
BMC Infectious Diseases
118 papers in training set
Top 5%
0.8%
29
Communications Medicine
85 papers in training set
Top 0.9%
0.8%
30
Nature
575 papers in training set
Top 16%
0.7%